NCT05524584View on ClinicalTrials.gov

Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

August 31, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2028

Conditions
Breast CancerMetastatic Breast CancerHormone Receptor-positive Breast CancerHER2-negative Breast Cancer
Interventions
DRUG

Fulvestrant

Given intramuscularly

DRUG

Anastrozole

Given orally

DRUG

Abemaciclib

Given orally

Trial Locations (1)

92868

Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange

All Listed Sponsors
lead

University of California, Irvine

OTHER